COMMENT Concert Pharmaceuticals discontinues schizophrenia drug after trial failure Exploring the pharma deals outlook in 2021 Market insight Medical cannabis in Europe Arriello director of drug safety, Peter Kohut examines the potential of medical cannabis in Europe comment Lodo Therapeutics’ AI-driven natural drug discovery insight Market access of orphan designated therapies at risk Concert Pharmaceuticals discontinues schizophrenia drug after trial failure Exploring the pharma deals outlook in 2021 02/23/2024 23:26:16
Concert Pharmaceuticals discontinues schizophrenia drug after trial failure
Exploring the pharma deals outlook in 2021